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CASE REPORTSValve with exchangeable biologic leafletsAdrian Ebner, MD,a Geoffrey K.-G. Svensson,b W. Randolph Chitwood, MD,c Joseph F. Sabik III MD,b and
Lars G. Svensson, MD, PhD,b Asuncion, Paraguay, Cleveland, Ohio, and Greenville, NCThere has long been a need for a biologic valve that is easy
to insert, safe, and durable, with low transvalvular pressure
gradients and no anticoagulation requirement.1 Despite re-
cent advances in biologic valve leaflet treatments with glu-
taraldehyde, alcohol, ethylene, and surfactant, biologic
valves are not routinely recommended—particularly for
younger patients—because of the risk of valve leaflet failure
with time.1 This report describes a valve with an easy-to-
insert base and exchangeable biologic leaflet set with low
pressure gradients to allow the easier replacement of
leaflets.FIGURE 1. The design of the valve incorporates (1) flexible stent posts,
(2) a well-controlled central gap, (3) precise stent circularity, and (4)
120 leaflet symmetry. The base and ribbon that support the leaflets are fab-
ricated from polyaryletherketone, a hard, fatigue-resistant medical-grade
polymer. The ribbon is held in place by bars that lock underneath hooks
on the base. Pericardial leaflets fill the gap between the ribbon and the
base. These leaflets are under some compression and act as a gasket to pre-
vent any leakage between the 2 mating components during valve function.
The base component is rigid to prevent deformation.MATERIALS AND METHODS
The 2-part valve consists of a stiff, low-profile polymer base, 3 commis-
sure attachment posts, and a polyester sewing cuff for intra-annular or
supra-annular attachment. An engineering drawing of the 2-part valve
frame is shown in Figure 1. The leaflets are composed of 3 laser-cut, me-
chanically matched pericardial leaflets attached to a flexible polymer
ring, with commissures attached to the base posts. The leaflet pericardium
is treated with ethanol and surfactants.
This valve’s base and leaflet set were designed to replicate a 23-mm
supra-annular valve. Designs were tested and refined until the valve dem-
onstrated lower gradients, larger comparative orifice area (effective orifice
area), and better long-term pulse duplicator durability than commercially
available valves. Hydrodynamic testing showed that the valve exceeded
both CE Mark and Food and Drug Administration requirements for bio-
logic valves (survived 200 million cycles at double the required closing
pressure, ejected more than 96% of forward flow, had greater effective
orifice area for size and lower pressure gradients).
The trial to test the new valve in patients was approved by The Italian
Hospital Ethics Committee at Asuncion and the Paraguay Ministry of
Health. Three male patients with aortic valve stenosis (aged 49, 62, and
72 years) were screened by preoperative transthoracic echocardiography,
had consent obtained, and were scheduled for the implant procedure.
The first 2 patients had bicuspid valves, and the third had senile degenera-
tion of a trileaflet valve. Preoperative peak and mean gradients and areas
were 110/72 mm Hg and 0.66 cm2; 47/23 mm Hg and 0.85 cm2; and
135/88 mm Hg and 0.43 cm2.
Standard aortic valve replacement technique was used, with cardiopul-
monary bypass, cardioplegia, ‘‘hockey stick’’ incision, and annular prepara-
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The Journal of Thoracic and Cathird was inserted with supra-annular sutures. After placement through the
native annulus, the sutures were passed through the sewing ring of the valve
base and tied in a standard fashion. Three clear plastic shields protected the
hooks on the approximately 6-mm tall stent posts (Figure 2). This valve’s
shorter stent posts and protective shields made tying the sutures easier
than with conventional biologic valves with taller posts. The leaflets did
not obstruct or hinder inspection after valve insertion, and additional valve
sutures were easily placed in each patient (for annular frailty, a broken
suture, and an ‘‘air knot’’). Once the base was secured, the leaflet set was
clipped into position, tested for strength of attachment, and internally
inspected for proper mating with no gaps. After aortic closure, transesopha-
geal echocardiographywas repeated. Patients wereweaned from cardiopul-
monary bypass, and closure was performed in the standard fashion.RESULTS
Intraoperative transesophageal echocardiography showed
no aortic valve or perivalvular regurgitation. Peak and mean
gradients were 18/7 mm Hg, 14/7 mm Hg, and 17.3/7.5 mm
Hg. Leaflet attachment took 3 to 6 minutes. All 3 patients
survived the procedure, with no strokes and no blood trans-
fusions. Thirty-day echocardiograms showed mean gradi-
ents of 19 mm Hg, 8 mm Hg, and 11 mm Hg. Effective
orifice areas were 1.87 cm2, 1.79 cm2, and 1.6 cm2. One
patient had mild to moderate perivalvular regurgitation.
There was no intravalvular regurgitation. Ninety-day echo-
cardiograms showed mean gradients of 3.6 mm Hg, 2.2rdiovascular Surgery c Volume 144, Number 2 e13
FIGURE 2. The valve base includes 3 clear, pliable shields that cover the
hooks and prevent the sutures from tangling during insertion. These shields
also act as soft tissue retractors to facilitate greater exposure and visualiza-
tion during attachment of the leaflet set.
Case Reportsmm Hg, and 2.0 mm Hg. Effective orifice areas at that time
were 1.35 cm2, 1.74 cm2, and 1.35 cm2. At 90 days of
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One other report has described an easy-to-insert valve
with separate components for insertion and removal.2 In
our 3-patient cohort, the valve was easy to insert, and the
shields protecting the stent posts facilitated suture tying.
The valve’s leaflets did not obstruct inspection and place-
ment of additional sutures. Overall valve performance was
excellent.
Safety and durability should be assessed in a larger series
of patients. Valve replacement through a transapical
approach is currently being investigated, and a working
engineering model shows that a transapical approach and
leaflet set exchange may be possible.References
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Tex Heart Inst J. 1987;14:31-8.Giant vein graft pseudoaneurysm with pulmonary hemorrhageZain Khalpey, MD, PhD, MRCS,a Edo Bedzra, MS,b Michael H. Stella, MD,c and Patrick O. Myers, MD,a
Boston, MassSaphenous vein graft (SVG) aneurysms, especially giant
ones with severe dilatation, are rare and present with non-
specific symptoms. They occur about 1 decade after sur-
gery and can be life-threatening, with an in-hospital
mortality of 15.7%.1 Covered stents have been increas-
ingly used for aneurysm treatment instead of classic surgi-
cal excision.2 The success of the intervention is time
dependent. We report a death from multisystem failure
after delayed SVG aneurysm exclusion using covered
stent grafts.CASE REPORT
An 83-year-old man, who had previously undergone cor-
onary artery bypass grafting 3 decades earlier, underwent
a reoperation for a failed circumflex graft, a stenotic poste-
rior descending artery graft, and aortic valve replacement
for aortic stenosis. His left anterior descending (LAD)
SVG was satisfactory at the time. Three years later, he
underwent repeat cardiac catheterization at another institu-
tion that showed a 100% ostial lesion of the LAD and
a 70% lesion proximal to the distal LAD anastomosis.
A heparin-coated stent was deployed for a 100% ostial
lesion in the right coronary artery. No particularities were
noted regarding the SVG. This was complicated by progres-
sive congestive heart failure, with the ejection fraction
reduced to 35%.
The patient developed hemoptysis, was diagnosed with
bronchitis and bronchiectasis, and was treated with bron-
chodilators and antibiotics. He did not have another epi-
sode until 4 months later, when he presented with
massive hemoptysis. He remained hemodynamically sta-
ble during the transfer to our institution and denied short-
ness of breath or chest pain. Bronchoscopy showed
bleeding in the airway, with right-sided bleeding greaterery c August 2012
